Brandes AA - Search Results

1

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844

2

Early chemotherapy and concurrent radio-chemotherapy in high grade glioma.

Brandes AA, Rigon A, Zampieri P, Scelzi E, Amistà P, Berti F, Rotilio A, Gardiman M, Fiorentino MV. Brandes AA, et al. J Neurooncol. 1996 Dec;30(3):247-55. doi: 10.1007/BF00177276. J Neurooncol. 1996. PMID: 8943100 Clinical Trial.

3

Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.

Brandes AA, Scelzi E, Zampieri P, Rigon A, Rotilio A, Amista P, Berti F, Fiorentino MV. Brandes AA, et al. Am J Clin Oncol. 1997 Aug;20(4):364-7. doi: 10.1097/00000421-199708000-00008. Am J Clin Oncol. 1997. PMID: 9256890 Clinical Trial.

4

Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study.

Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV. Brandes AA, et al. Eur J Cancer. 1997 Sep;33(10):1592-6. doi: 10.1016/s0959-8049(97)00167-6. Eur J Cancer. 1997. PMID: 9389920

5

Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.

Brandes AA, Rigon A, Zampieri P, Ermani M, Carollo C, Altavilla G, Turazzi S, Chierichetti F, Florentino MV. Brandes AA, et al. Cancer. 1998 Jan 15;82(2):355-61. doi: 10.1002/(sici)1097-0142(19980115)82:2<362::aid-cncr17>3.0.co;2-x. Cancer. 1998. PMID: 9445194 Clinical Trial.

6

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.

Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistà P, Rotilio A, Licata C, Fiorentino MV. Brandes AA, et al. J Clin Oncol. 1999 Feb;17(2):645-50. doi: 10.1200/JCO.1999.17.2.645. J Clin Oncol. 1999. PMID: 10080610 Clinical Trial.

7

Temozolomide in patients with high grade gliomas.

Brandes AA, Pasetto LM, Vastola F, Monfardini S. Brandes AA, et al. Oncology. 2000 Sep;59(3):181-6. doi: 10.1159/000012158. Oncology. 2000. PMID: 11053983 Review.

8

Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors.

Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P. Lumachi F, et al. Among authors: brandes aa. Anticancer Res. 2000 Nov-Dec;20(6C):4751-5. Anticancer Res. 2000. PMID: 11205212

9

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Brandes AA, et al. Ann Oncol. 2001 Feb;12(2):255-7. doi: 10.1023/a:1008336732273. Ann Oncol. 2001. PMID: 11300334 Free article. Clinical Trial.

10

New strategy developments in brain tumor therapy.

Brandes AA, Basso U, Pasetto LM, Ermani M. Brandes AA, et al. Curr Pharm Des. 2001 Nov;7(16):1553-80. doi: 10.2174/1381612013397221. Curr Pharm Des. 2001. PMID: 11562299 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

322 results

Search Page

Filters